These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 22943413)

  • 1. Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase IV inhibitors.
    Sharma M; Gupta M; Singh D; Kumar M; Kaur P
    Chem Biol Drug Des; 2012 Dec; 80(6):918-28. PubMed ID: 22943413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, evaluation and molecular docking of prolyl-fluoropyrrolidine derivatives as dipeptidyl peptidase IV inhibitors.
    Sharma M; Gupta M; Singh D; Kumar M; Kaur P
    Chem Biol Drug Des; 2013 Aug; 82(2):156-66. PubMed ID: 23581745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of thiouracil derivatives as dipeptidyl peptidase IV inhibitors.
    Sharma M; Singh D; Gupta M
    Chem Biol Drug Des; 2013 Feb; 81(2):257-64. PubMed ID: 23039850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors.
    Liu Y; Si M; Tang L; Shangguan S; Wu H; Li J; Wu P; Ma X; Liu T; Hu Y
    Bioorg Med Chem; 2013 Sep; 21(18):5679-87. PubMed ID: 23938053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, structure-activity relationships, and docking studies of 1-(γ-1,2,3-triazol substituted prolyl)-(S)-3,3-difluoropyrrolidines as a novel series of potent and selective dipeptidyl peptidase-4 inhibitors.
    Zhang L; Su M; Li J; Ji X; Wang J; Li Z; Li J; Liu H
    Chem Biol Drug Des; 2013 Feb; 81(2):198-207. PubMed ID: 22994702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of dipeptidyl peptidase IV inhibitors: virtual screening, synthesis and biological evaluation.
    Xing J; Li Q; Zhang S; Liu H; Zhao L; Cheng H; Zhang Y; Zhou J; Zhang H
    Chem Biol Drug Des; 2014 Sep; 84(3):364-77. PubMed ID: 24674599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovering novel α-aminoacyl-containing proline derivatives with potent and selective inhibitory activity against dipeptidyl peptidase IV: design, synthesis, biological evaluation, and molecular modeling.
    Zhang X; Wang J; Su M; Li Z; Li J; Li J; Liu H
    Chem Biol Drug Des; 2012 Dec; 80(6):843-52. PubMed ID: 22726613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.
    Banno Y; Miyamoto Y; Sasaki M; Oi S; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Tsubotani S; Tani A; Funami M; Tawada M; Yamamoto Y; Aertgeerts K; Yano J; Maezaki H
    Bioorg Med Chem; 2011 Aug; 19(16):4953-70. PubMed ID: 21764322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors.
    Deng X; Han L; Zhou J; Zhang H; Li Q
    Bioorg Chem; 2017 Dec; 75():357-367. PubMed ID: 29096096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, structure-activity relationship, and pharmacophore modeling studies of pyrazole-3-carbohydrazone derivatives as dipeptidyl peptidase IV inhibitors.
    Wu D; Jin F; Lu W; Zhu J; Li C; Wang W; Tang Y; Jiang H; Huang J; Liu G; Li J
    Chem Biol Drug Des; 2012 Jun; 79(6):897-906. PubMed ID: 22381062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
    Maezaki H; Banno Y; Miyamoto Y; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Sasaki M; Tsubotani S; Tani A; Funami M; Yamamoto Y; Tawada M; Aertgeerts K; Yano J; Oi S
    Bioorg Med Chem; 2011 Aug; 19(15):4482-98. PubMed ID: 21741847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes.
    Kushwaha RN; Srivastava R; Mishra A; Rawat AK; Srivastava AK; Haq W; Katti SB
    Chem Biol Drug Des; 2015 Apr; 85(4):439-46. PubMed ID: 25216392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors.
    Patel BD; Bhadada SV; Ghate MD
    Bioorg Chem; 2017 Jun; 72():345-358. PubMed ID: 28302310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors.
    Li Q; Han L; Zhang B; Zhou J; Zhang H
    Org Biomol Chem; 2016 Oct; 14(40):9598-9611. PubMed ID: 27714283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site.
    Nabeno M; Akahoshi F; Kishida H; Miyaguchi I; Tanaka Y; Ishii S; Kadowaki T
    Biochem Biophys Res Commun; 2013 May; 434(2):191-6. PubMed ID: 23501107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
    Deng J; Peng L; Zhang G; Lan X; Li C; Chen F; Zhou Y; Lin Z; Chen L; Dai R; Xu H; Yang L; Zhang X; Hu W
    Eur J Med Chem; 2011 Jan; 46(1):71-6. PubMed ID: 21106276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.
    Wang J; Feng Y; Ji X; Deng G; Leng Y; Liu H
    Bioorg Med Chem; 2013 Dec; 21(23):7418-29. PubMed ID: 24153396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Yoshida T; Akahoshi F; Sakashita H; Kitajima H; Nakamura M; Sonda S; Takeuchi M; Tanaka Y; Ueda N; Sekiguchi S; Ishige T; Shima K; Nabeno M; Abe Y; Anabuki J; Soejima A; Yoshida K; Takashina Y; Ishii S; Kiuchi S; Fukuda S; Tsutsumiuchi R; Kosaka K; Murozono T; Nakamaru Y; Utsumi H; Masutomi N; Kishida H; Miyaguchi I; Hayashi Y
    Bioorg Med Chem; 2012 Oct; 20(19):5705-19. PubMed ID: 22959556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural optimization of pyrazolo[1,5-a]pyrimidine derivatives as potent and highly selective DPP-4 inhibitors.
    Shen J; Deng X; Sun R; Tavallaie MS; Wang J; Cai Q; Lam C; Lei S; Fu L; Jiang F
    Eur J Med Chem; 2020 Dec; 208():112850. PubMed ID: 32987315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.